Hims & Hers has launched its Weight Loss Programme in the UK, including the introduction of the Hers platform for women. The digital health platform provides access to weight management care for eligible customers.
Following an intake assessment conducted by GMC-registered doctors, eligible customers have access to personalized weight management programmes, which may include branded GLP-1 options such as Mounjaro or Wegovy, and the oral non-prescription treatment option Orlos. Licensed clinicians assess each individual’s medical history, suitability, and contraindications to guide treatment decisions.
All customers have access to 24/7 care team support and content to help improve nutrition, movement, and sleep-based habits. The programme is designed to support long-term health and help customers manage weight and adopt sustainable lifestyle habits.
“The launch of Hims & Hers’ comprehensive Weight Loss Programme and the vital introduction of the Hers platform, our dedicated platform for women, represents a significant deepening of our commitment to the UK,” said David Meinertz, GM International of Hims & Hers. “Our doctor-designed treatment plans will complement the NHS by providing accessible, evidence-based, and sustainable long-term weight management care to those who need it, discreetly and conveniently.”
Hers customers receive ongoing clinician support through follow-ups and asynchronous messaging, along with treatment adjustments when necessary. The platform provides ongoing access to GMC-registered doctors.
“Obesity is a global epidemic, and the scale of the challenge in the UK requires a comprehensive solution that prioritises long-term health over quick fixes,” said Craig Primack MD, Head of Weight Loss at Hims & Hers. “Bringing our trusted, comprehensive approach to the UK will help people lead fuller and healthier lives. And with the launch of the Hers platform, we are ensuring women have access to the dedicated, personalised care they need.”
Sixty-four percent of UK adults are overweight or living with obesity. Access to GLP-1 treatment plans remains challenging on the NHS and via the private sector due to demand and costs.
Hims & Hers plans to expand into additional offerings as demand for personalized care grows in the UK.
